Expected Upcoming Milestones: Q3 CY2024: Report 4-6 week data from first five lead-in patients in ongoing PoC human clinical trial; Q4 CY2024: Complete enrollment in PoC human clinical trial evaluating proprietary ablation technology for treatment of pancreatic cancer pain; 2024: Complete ablation device design intended for clinical use; 1H 2025: Report topline data from PoC human clinical trial; 2025: Complete development of ablation system and catheters in preparation for human pivotal trial; 2025: Initiate combined sensing / ablation clinical trial; 2026: De novo submission; and 2027: FDA clearance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMIX:
- Autonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near-Term Milestones
- Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment
- Autonomix completes licensing transaction for FDA-cleared ablation technology
- Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
- Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Covering Technology License Agreement
Questions or Comments about the article? Write to editor@tipranks.com